Advanced search
Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Email Registration
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Avidity Biosciences, Inc.
  6. News
  7. Summary
    RNA   US05370A1088

AVIDITY BIOSCIENCES, INC.

(RNA)
  Report
Delayed Nasdaq  -  04:00:01 2023-02-07 pm EST
25.50 USD   +4.94%
09:01aAvidity Biosciences to Participate in Upcoming Investor Conference
PR
02/03Insider Sell: Avidity Biosciences
MT
01/20Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PR
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Chardan Research Adjusts Price Target for Avidity Biosciences to $27 From $29, Maintains Buy Rating

09/27/2022 | 02:59pm EST
share with twitter
share with LinkedIn
share with facebook


© MT Newswires 2022
All news about AVIDITY BIOSCIENCES, INC.
09:01aAvidity Biosciences to Participate in Upcoming Investor Conference
PR
02/03Insider Sell: Avidity Biosciences
MT
01/20Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PR
01/18Avidity Biosciences Says it Received FDA's Fast Track Designation for AOC 1020 to Treat..
MT
01/18Avidity Biosciences Gets FDA Fast-Track Designation for AOC 1020
DJ
01/18Avidity Biosciences Granted FDA Fast Track Designation for AOC 1020 for the Treatment o..
PR
01/18Avidity Biosciences Granted FDA Fast Track Designation for AOC 1020 for the Treatment o..
CI
01/06Avidity Biosciences : January 2023 Corporate Presentation
PU
01/04Wells Fargo Adjusts Price Target on Avidity Biosciences to $55 From $60, Maintains Over..
MT
01/03Insider Sell: Avidity Biosciences
MT
More news
Analyst Recommendations on AVIDITY BIOSCIENCES, INC.
More recommendations
Financials (USD)
Sales 2022 8,33 M - -
Net income 2022 -173 M - -
Net cash 2022 371 M - -
P/E ratio 2022 -7,24x
Yield 2022 -
Capitalization 1 615 M 1 615 M -
EV / Sales 2022 149x
EV / Sales 2023 210x
Nbr of Employees 125
Free-Float 76,6%
Chart AVIDITY BIOSCIENCES, INC.
Duration : Period :
Avidity Biosciences, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends AVIDITY BIOSCIENCES, INC.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 8
Last Close Price 24,30 $
Average target price 43,29 $
Spread / Average Target 78,1%
EPS Revisions
Managers and Directors
Sarah Boyce President, Chief Executive Officer & Director
Michael F. MacLean Chief Financial & Accounting Officer
Troy E. Wilson Non-Executive Chairman
Arthur A. Levin Chief Scientific Officer
W. Michael Flanagan Chief Technical Officer
Sector and Competitors
1st jan.Capi. (M$)
AVIDITY BIOSCIENCES, INC.9.51%1 615
CSL LIMITED8.40%103 363
SAMSUNG BIOLOGICS CO.,LTD.-0.97%45 550
BIOGEN INC.2.42%41 513
WUXI BIOLOGICS (CAYMAN) INC.6.10%34 193
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.8.28%22 564